Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Inflammatory bowel diseases (IBD) and their treatments, particularly immunosuppressive
drugs, increase risk of infections and cancers. However, by promoting mucosal healing …

Background Randomised placebo-controlled trials for the induction of inflammatory bowel
disease (IBD) remission involve potential harms to those receiving placebo. Whether these …

Background Randomised placebo-controlled trials are the gold standard to assess novel
drugs in ulcerative colitis and Crohn's disease. However, there might be risks associated …

The use of corticosteroids to treat patients with inflammatory bowel disease [IBD] has been
the bedrock of IBD therapeutics since the pioneering work of Truelove and Witts in the UK in …

Patients with inflammatory bowel disease (IBD) are at an increased risk for venous
thromboembolism (VTE). VTE events carry significant morbidity and mortality, and have …

Patients with inflammatory bowel disease (IBD) have an increased risk of developing
venous thromboembolic events, which have a considerable impact on morbidity and …

Cardiovascular and thromboembolic risks are increasing in the population as a whole and
therefore also in inflammatory bowel disease (IBD) patients. Obesity is a worldwide …

Background: We aimed to systematically assess a possible association of tofacitinib therapy
with cardiovascular events (CVEs) and all-cause mortality. Methods: Systematic searches of …

Purpose This study assessed the association between thromboembolic events (TEs) and
immune-mediated diseases (IMDs) and characterized the risk profile of TEs among patients …